Tumeurs solides

  • Accueil
  • Tumeurs solides
  • CA233-0000

TITRE (EN) A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies
PROTOCOLE ID CA233-0000
CLINICAL TRIAL.gov ID NCT06544655
TYPE(S) DE CANCER Tumeurs solides
PHASE Phase I
TYPE D'ÉTUDE Clinique
INSTITUTION CHUM
1051 rue Sanguinet
(514) 890-8000
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Rahima Jamal
COORDONATEUR(RICE) Adeline Hamon
parc.eligibilite.chum@ssss.gouv.qc.ca
514-890-8000 poste 30737
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
  • Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
  • Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
CRITÈRES D'EXCLUSION (EN)
  • History of or with active interstitial lung disease or pulmonary fibrosis.
  • Active, known, or suspected autoimmune disease.
  • Serious uncontrolled medical disorders.
  • New onset, non-catheter-associated venous thromboembolism within the past 6 months.
  • Other protocol-defined Inclusion/Exclusion criteria apply.